I just came back from IMCAS Paris, where BCG, McKinsey, and Wells Fargo sat in the same room with medical aesthetics executives and laid out the state of the industry with no filter.
Here's what most people will take away: 5% growth. North America down $200M. HA fillers under pressure. Energy-based devices struggling with 17% financing rates.
Here's what most people will miss entirely.
Sergio Rossi, Senior Partner and Managing Director at BCG, posed a question that should be sitting in every C suite right now: "We are happy with the 5% growth of the market but how can we double the size of the market, considering that this is a market with a lot of underpenetrated opportunities?"
Not optimize. Not stabilize. **Double.**
The global aesthetics market sits at approximately $20 to $25B today. BCG's thesis is that it could reach $60B if the industry stops thinking in products and starts thinking in ecosystems. That is not a modest forecast. That is a structural argument for what's possible when sophisticated players stop fighting over existing market share and start activating the consumers who haven't entered the category yet.
That's the story. And most people in this industry are going to miss it because they're too busy staring at the HA filler decline.
---
The Recalibration Nobody Wants to Name
Let me be direct about what the data actually showed.
Growth has slowed from 7 to 8% historically down to 5%. That matters. The North American market lost $200M in 2025. HA fillers were down 8%. Energy-based devices are facing capital constraint headwinds that aren't going away while interest rates stay elevated. These are real numbers from serious analysts Raghav Tangri at Checkers Healthcare, Mike Moretti as Global Market Research Analyst, Sergio at BCG not industry cheerleading.
Mike Moretti said it plainly: "There is no rosy color here. We need to address fundamentals ethical behavior, innovation, and how we treat customers."
This is a recalibration. Not a decline. There's an important difference, and the executives who understand that distinction are already positioning for what comes next while their competitors are still trying to figure out what went wrong.
---
Three Shifts That Actually Matter
1. The Consumer Is Already Educated. Act Accordingly.
The industry has operated for decades on a supply-driven model. Physicians held the authority. Patients were passive recipients of recommendations. That era is over.
Consumers are arriving at practices already educated from Google, from social media, from AI tools that didn't exist three years ago. They've formed opinions before they walk in the door. As Michel, CEO of Obagi, put it on the panel, the imperative now is reaching consumers with accurate information before they find it on Google, Wikipedia, or worse places.
The strategic question is no longer how do we educate our providers. It's how do we reach consumers before they form their opinions through unreliable sources.
This is why the shift from "patients" to "consumers" a point that came up repeatedly across panels is not just semantic. It's a power dynamic acknowledgment. The brands and practices that understand this are investing in consumer activation. The ones that don't are watching their conversion rates get harder to explain.
2. The Silver Economy Is a $22 Trillion Opportunity That Aesthetics Is Barely Touching
The Global Coalition on Aging presented data that should reframe every strategic conversation happening in this industry right now.
There are 2 billion people over 55 globally today. That number is doubling. In OECD countries, 70% of wealth is held by people 60 and older. In the US alone, that demographic represents 50% of the addressable market and it is growing far faster than younger populations.
BlackRock's Larry Fink dedicated his 2025 annual letter to age demographics. Bank of America is paying attention. Major travel and hospitality players are repositioning. The United Nations launched a Decade of Healthy Aging with all 193 member governments signed on.
Medical aesthetics sits at the precise intersection of health, wellness, and longevity that this demographic is actively seeking. The opportunity is not anti-aging messaging that framing is finished. The opportunity is aging with quality of life. Preventative protocols. Sustained engagement across a lifetime rather than episodic intervention.
This is not a niche. This is a $22 trillion marketplace that the medical aesthetics industry is dramatically underpenetrated in.
3. Ecosystem Orchestration Is the New Competitive Moat
The most important strategic conversation at the forum wasn't about a single product category. It was about ecosystem thinking and it played out in real time across a panel of executives from BCG, Revance, Evolus, and Obagi who each described what it actually looks like to build one.
Sergio at BCG framed the thesis: the companies winning the next decade won't win on product alone. They'll win by owning the consumer journey across consumer orchestration, product orchestration, and wellness integration. The question he left the room with was whether the industry wants to engage in a price war, or offer something more.
Jeff Bedard of Revance put it in terms every strategist should write down: "That patient is a white canvas, and we as industry supply the paints and the brushes. The more that you can supply different colors, a fine brush, a broad brush, the more important within that ecosystem you're going to be but they all have to work together." His framework for the consumer journey was equally clear: prevention gets them in their youth, regeneration is the massive opportunity as they age, and AI enablement takes the friction out of the entire process.
David from Evolus described what this looks like operationally co-branding with clinics on every consumer touchpoint, advertising locally within a clinic's radius, building loyalty programs that direct consumers back to specific partner practices, and leading with a beauty lens rather than clinical messaging because younger consumers want approachable brands, not medical authority.
Consumer orchestration means engaging people outside the practice before they've formed their opinions. Product orchestration means building combination protocols with scientific backing and measurable outcomes. Wellness integration means partnering beyond pharma Sergio noted that 50% of esthetic consumers are already on nutrition plans, and the inside-out approach represents an adjacency that sophisticated players are beginning to move into.
The companies that win the next decade in this industry will not win because they have the best single product. They will win because they own the consumer journey from first digital touchpoint to lifetime loyalty.
---
What This Means If You're Making Strategic Decisions Right Now
The categories with genuine tailwinds: bio-stimulators, physician-dispensed topicals, neuromodulators, skin tightening. The geographic opportunities being systematically underestimated by Western-focused companies: APAC, LATAM, and the Middle East.
The GLP-1 narrative is more nuanced than anyone's headline suggests. Lee Jensen, Partner at McKinsey and former plastic surgeon, mapped four distinct patient archetypes emerging from GLP-1 adoption from high-spending Maximizers to Value Seekers to Surgical Resolvers and across all four, HA fillers, neuromodulators, and skincare remain mainstays. The GLP-1 story is not a tide lifting all boats. It is a segmentation opportunity for practices and brands sophisticated enough to tailor their approach accordingly. And as one physician on the panel noted, the micro-dosing segment is growing patients who want to feel and look a little better, not undergo dramatic transformation. That's a different consumer than the one most companies are currently building for.
And on price competition: 150 plus filler companies currently exist. The combined effect of widespread price cutting has produced demand at 7 to 9% but realized growth of only 5% due to price erosion. The question Sergio posed at the forum is the right one do we want to engage in a price war, or offer something more?
The answer, for anyone building a sustainable business in this industry, should be obvious.
---
My Take
I've built my practice around a single conviction: the companies and executives who will define this industry over the next decade are not the ones chasing the trend. They're the ones building authority infrastructure while everyone else is distracted by the noise.
The IMCAS 2026 Economic Forum confirmed something I've been telling my clients for years. The window for differentiation is not closing. It is open, right now, for the players willing to think at the ecosystem level while their competitors are still arguing about syringe counts.
The opportunity is not smaller than it was. For the executives willing to think bigger than the current headlines, it's substantially larger.
---
*Leslie is the author of* Be Intentional or Be Irrelevant *and the founder of Diamond Hands Media.*